Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05858645 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Correction of Psoriatic T Cell Signatures by Deucravacitinib

Name: Correction of Psoriatic T Cell Signatures by Deucravacitinib — clinical trial record (NCT05858645)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 4

SponsorUniversity of California, San Francisco

Started2023-10-01

View on ClinicalTrials.gov ↗

Amendment history

2026-06-01

Study Status v2

Primary completion date2026-06→2028-06

Completion date2026-06→2028-06

2024-06-25

Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v1

Trial statusNot Yet Recruiting→Recruiting

Start dateestimated 2023-07→confirmed 2023-10-01

Study sitesdetails revised at 1 of 1 site

2023-05-04

Original filing

University of California, San Francisco

637 trials monitored

See 53 trials at risk

Psoriasis

418 trials monitored

See 17 trials at risk

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the Tyrosine kinase 2 (TYK2) blocker, deucravacitinib.

Trial Details

NCT Number	NCT05858645
Lead Sponsor	University of California, San Francisco Collaborators: Bristol-Myers Squibb
Conditions	Psoriasis Vulgaris
Enrollment	25 participants
Start Date	2023-10-01
Primary Completion	2028-06 (estimated)
Study Completion	2028-06 (estimated)
Updated on ClinicalTrials.gov	2026-06-04